 |
Prospector
Profile
07.1224
|
| |
| Nanogen, Inc. |
NAICS |
339100 |
| 10398 Pacific Center Court
San Diego, CA 92121 |
Description |
Medical Equipment Mfg. |
| (858) 587-1121 |
Employees |
288 |
| http://www.nanogen.com/ |
Revenue |
(mil) |
26.8520 |
| |
Income |
(mil) |
-49.0700 |
| |
Assets |
(mil) |
119.2530 |
| |
Liability |
(mil) |
59.0400 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Nanogen, Inc. reported a net loss of $14,531,000 on revenues of $10,315,000 for the three months ended June 30, 2007, compared to a net loss of $14,051,000 on revenues of $6,311,000 for the same quarter last year. For the six months ended June 30, 2007, the Company reported $26,379,000 in net loss, slightly higher than the net loss of $26,072,000 reported during the first half of last year. As a result of its recurring losses, the Company has an accumulated deficit of $387,105,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
In 2006, the Company was granted 26 U.S. patents, bringing its current total to 137 issued U.S. patents and numerous foreign patents expiring at varying dates. In addition, the Company has a number of pending patent applications filed in the U.S. and abroad. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company engages in the development, manufacture, and sale of advanced diagnostic products to research, clinical laboratory, and point of care markets in North America, Europe, and Asia.
|
| |
|
Officers:
Howard C. Birndorf (Chair & CEO): Robert Saltmarsh (CFO); David Schreiber (Dir.); Robert E. Whalen (Dir.); Stelios B. Papadopoulos (Dir.); William G. Gerber (Dir.); Heiner Dreismann (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol NGEN; NasdaqGM;
72,819,006 common shares outstanding as of July 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
